Climb Bio (NASDAQ:CLYM) Stock Gets Downgrade from Wall Street Zen

Climb Bio (NASDAQ:CLYM – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. Oppenheimer lifted their target price on shares of Climb Bio from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 8th. HC Wainwright restated a “buy” rating on shares of Climb Bio in a research report on Monday, October 12th. B. Riley Financial reaffirmed a “buy” rating on shares of Climb Bio in a research note on Friday, September 4th. Truist Financial lifted their price objective on Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Guggenheim reissued a “buy” rating on shares of Climb Bio in a research note on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $28.14.

Read Our Latest Stock Report on CLYM

Climb Bio Trading Down 4.7%

Shares of CLYM traded down $0.51 during mid-day trading on Friday, reaching $10.36. The company’s stock had a trading volume of 667,815 shares, compared to its average volume of 1,365,029. The stock has a market cap of $608.55 million, a PE ratio of -12.63 and a beta of 0.01. Climb Bio has a 52 week low of $1.63 and a 52 week high of $18.33. The company’s fifty day moving average price is $11.58 and its two-hundred day moving average price is $10.63.

Climb Bio (NASDAQ:CLYM – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Research analysts anticipate that Climb Bio will post -0.75 EPS for the current year.

Insider Activity

In related news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the transaction, the director directly owned 467,969 shares of the company’s stock, valued at $6,397,136.23. The trade was a 17.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Climb Bio

Large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Climb Bio in the third quarter valued at about $6,406,000. Empowered Funds LLC bought a new position in shares of Climb Bio during the third quarter valued at about $265,000. First Trust Advisors LP purchased a new stake in shares of Climb Bio during the third quarter worth about $490,000. State Street Corp boosted its holdings in shares of Climb Bio by 34.7% during the third quarter. State Street Corp now owns 1,850,010 shares of the company’s stock worth $21,220,000 after purchasing an additional 476,466 shares during the period. Finally, Fisher Asset Management LLC purchased a new stake in shares of Climb Bio during the third quarter worth about $505,000. Institutional investors own 69.76% of the company’s stock.

About Climb Bio

(Get Free Report)

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.

Further Reading

Analyst Recommendations for Climb Bio (NASDAQ:CLYM)

Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.